- Home
- CCIA vs LYEL Comparison
CCIA vs LYEL Comparison
Compare CCIA & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIA
- LYEL
- Stock Information
- Founded
- CCIA N/A
- LYEL 2018
- Country
- CCIA
- LYEL United States
- Employees
- CCIA N/A
- LYEL N/A
- Industry
- CCIA
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- CCIA
- LYEL Health Care
- Exchange
- CCIA Nasdaq
- LYEL Nasdaq
- Market Cap
- CCIA N/A
- LYEL 263.9M
- IPO Year
- CCIA 2023
- LYEL 2021
- Fundamental
- Price
- CCIA $25.74
- LYEL $0.65
- Analyst Decision
- CCIA
- LYEL Sell
- Analyst Count
- CCIA 0
- LYEL 2
- Target Price
- CCIA N/A
- LYEL $1.00
- AVG Volume (30 Days)
- CCIA N/A
- LYEL 1.3M
- Earning Date
- CCIA N/A
- LYEL 02-26-2025
- Dividend Yield
- CCIA N/A
- LYEL N/A
- EPS Growth
- CCIA N/A
- LYEL N/A
- EPS
- CCIA N/A
- LYEL N/A
- Revenue
- CCIA N/A
- LYEL $63,000.00
- Revenue This Year
- CCIA N/A
- LYEL N/A
- Revenue Next Year
- CCIA N/A
- LYEL N/A
- P/E Ratio
- CCIA N/A
- LYEL N/A
- Revenue Growth
- CCIA N/A
- LYEL N/A
- 52 Week Low
- CCIA N/A
- LYEL $0.58
- 52 Week High
- CCIA N/A
- LYEL $3.26
- Technical
- Relative Strength Index (RSI)
- CCIA 43.59
- LYEL 34.74
- Support Level
- CCIA $25.63
- LYEL $0.60
- Resistance Level
- CCIA $25.85
- LYEL $0.71
- Average True Range (ATR)
- CCIA 0.13
- LYEL 0.06
- MACD
- CCIA -0.01
- LYEL 0.01
- Stochastic Oscillator
- CCIA 30.11
- LYEL 23.51
About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.